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Background: FPR2/ALX is important in the resolution of the immune response.
Results: Truncation of the C-tail results in attenuated recycling, receptor degradation, and enhanced apoptosis.
Conclusion: The FPR2/ALX contains a C-terminal motif mediating receptor recycling following endocytosis providing pro-
tection against cellular apoptosis.
Significance: This work identifies a novel transferable recycling sequence that controls GPCR trafficking and describes the
cellular processes of the pro-resolution phase of the inflammatory response.
Formyl-peptide receptor type 2 (FPR2; also called ALX because
it is the receptor for lipoxin A4) sustains a variety of biological
responses relevant to the development and control of inflamma-
tion, yet the cellular regulation of this G-protein-coupled receptor
remains unexplored. Here we report that, in response to peptide
agonist activation, FPR2/ALX undergoes -arrestin-mediated
endocytosis followed by rapid recycling to the plasma membrane.
We identify a transplantable recycling sequence that is bothneces-
sary and sufficient for efficient receptor recycling. Furthermore,
removal of this C-terminal recycling sequence alters the endocytic
fate of FPR2/ALX and evokes pro-apoptotic effects in response to
agonist activation. This study demonstrates the importance of
endocytic recycling in the anti-apoptotic properties of FPR2/ALX
and identifies themolecular determinant required formodulation
of this process fundamental for the control of inflammation.
The inflammatory response is a defense mechanism devel-
oped to protect the host following an injury or infection. Once
triggered, a series of soluble and cellular “pro-inflammatory”
events is initiated resulting in swelling, redness, and pain. This
initial phase is followed by a pro-resolving process, serving to
restore tissue homeostasis (1). Failure of resolution leads to
chronic inflammation and is implicated in pathologies includ-
ing colitis (2) and asthma (3). One important group of receptors
regulating these processes consists of the formyl peptide recep-
tors (FPRs),3 which belong to the G-protein-coupled receptor
(GPCR) superfamily. GPCR signaling modulates a variety of
responses, from leukocyte activation andmigration, to apopto-
sis and phagocytosis. At the intracellular level, GPCR signaling
is controlled by a series of molecular events such as phosphor-
ylation, arrestin interaction (which also initiates G-protein-
independent signaling), desensitization, and endocytosis that
serve to titrate signaling at the cellular level (4). There is limited
understanding of the relationship between functional responses
and their association with specific intracellular events, espe-
cially when considering receptor endocytosis and recycling.
The human FPR family consists of three intriguing members
that bind a plethora of ligands to evoke several, often apparently
opposite, effects (for recent review, see Ref. 5). The receptor
that binds serum amyloid A, annexin-A1 (AnxA1), as well as
the bioactive lipidmediators lipoxin A4 (LXA4) and resolvin D1
is termed FPR2/ALX (where the designation ALX refers to
LXA4 receptor (6)). Both FPR1 and FPR2/ALX undergo ago-
nist-induced endocytosis mediated via distinct mechanisms.
Interestingly, FPR1 endocytosis is independent of either clath-
rin-mediated (7) or arrestin-mediated pathways (8–10),
whereas the internalization of FPR2/ALX seems dependent on
both (11, 12). Both receptors are rapidly recycled back to the
plasma membrane following agonist removal; however,
although FPR1 recycling requires the binding of both arrestins
and adaptor protein 2 (AP2) (10, 13), little is known about the
FPR2/ALX recycling process.
Numerous studies have implicated theC-tail ofGPCRs in the
regulation of cellular signaling and endocytosis (4), containing
motifs that serve to bind sorting proteins and influence recep-
tor fate. A series of elegant studies has systematically investi-
gated specific clusters of serine and threonine residues within
the C-tail of both the FPR1 (14–17) and the FPR2/ALX (18),
demonstrating that, similar to other GPCRs, phosphorylation
of specific serines in the region was critical for efficient phos-
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phorylation and desensitization of either receptor. Whether
these residues are important for regulating endocytosis or
deciding cellular fate has yet to be elucidated.
Using the information previously reported for phosphorylation
sites in FPR1 (14–17) and FPR2/ALX (18), we sought to investi-
gate the importance of theC-tail in FPR2/ALXrecycling following
endocytosis in response to its potent agonistWKYMVm (Wpep-
tide). We identify a specific sequence in the C-terminal tail of
FPR2/ALX necessary for the efficient recycling of this receptor
that also modulates cell sensitivity to apoptosis.
EXPERIMENTAL PROCEDURES
Drugs and Reagents—FLAG M1 and FLAG M2 antibodies
were purchased from Sigma. Alexa Fluor 594 IGg2b, Alexa
Fluor 647 antibody labeling kit, LysoTracker Red DND-99,
and Lipofectamine 2000 were from Life Technologies.
WKYMVm peptide was purchased from Tocris, and [D-Ala-2,
D-Leu-5]-enkephalin (DADLE) was purchased from Sigma.
Propidium iodide and annexin V kit were purchased from Cell
Signaling Technology. Total and phospho-ERK 1/2 and JNK
antibodies were purchased from Cell Signaling Technology.
Cell Culture Constructs and Transfections—cDNAs of
human FPR2/ALX and FPR1 (Missouri S&T cDNA Resource
Center) were amplified by PCR (PfuUltra hotstart turbo, Agi-
lent Technologies) and ligated into N-terminal signal sequence
FLAG-tagged vectors (gift fromMark Von Zastrow, University
of California, San Francisco (UCSF)). All truncations, point
mutations, and amino acid additions were introduced by site-
directed mutagenesis (PfuUltra, Agilent technologies). EGFP-
-Arr1, EGFP--Arr2, and EGFP-RAB5 were kind gifts from
Prof. Mark von Zastrow (UCSF). EGFP-Rab11 was a kind gift
from Dr. Rey Carabeo (University of Aberdeen).
Cell Culture and Immunocytochemistry—Constructs were
either transiently or stably expressed in HEK293 cells and
grown to 50% confluency on glass coverslips coated in 1% gel-
atin. Receptors where co-expressed with enhanced green fluo-
rescence protein (EGFP) constructswhere indicated. Cellswere
fed with anti-FLAG M1 antibody (1:1000, 30 min) to label
mature cell surface receptors (as described previously (19)) and
incubated with agonist for indicated time points, then fixed,
blocked, and permeabilized and stained with fluorescently conju-
gated secondary antibody (1:1000). For LysoTracker experiments,
cells were serum-starved and incubated with 100 nM LysoTracker
RedDND-99 for 2 h prior to experimentation. For co-localization
of receptor constructs with -Arr2 at 30 min of W peptide treat-
ment, at least 30 cells from three independent experiments were
analyzed and quantified according to the proportion of pixels that
were both red and green using Pearson’s rank coefficient as part of
the ImageJ plugin Coloc 2 (rsb.info.nih.gov/ij/).
Flow Cytometry—Anti-FLAG M1 antibody was conjugated
to Alexa Fluor 647 dye according to the manufacturer’s
instructions. HEK293 cells expressing N-terminally tagged
constructs were subjected to a modified version of antibody
feeding and flow cytometry (20, 21). Cells were incubated for 30
min with M1 Alexa Fluor 647 (1:1,000), to label only surface
receptors, and then stimulated for 30 min with agonist. Cells
were washed with PBS/EDTA (2 mM) to remove residual anti-
body from remaining surface receptors and either resuspended
in PBS (containing Ca2 and Mg2) to measure endocytosis
(represented by an increase in fluorescence, indicative of endo-
cytosed receptor protected from the strip wash) or returned to
the incubator for 15, 30, 60, or 90min in PBS containing EDTA
to measure recycling (as determined by a loss of fluorescence
due to receptors returning to the plasma membrane and being
stripped of their label). After all treatments, cells were pelleted,
washed, and resuspended in PBS (containing Ca2 andMg2).
Samples were analyzed using a FACSCalibur (BD Biosciences)
with 10,000 events being analyzed in all cases.
Biotin Protection Degradation Assay—HEK293 cells stably
expressing N-terminal FLAG-tagged FPR2/ALX, N333-stop,
P342-stop, or T346-stop were grown to 100% confluency and
labeled with 3 g/ml disulfide-cleavable biotin (Pierce) for 30
min at 4 °C (19). Cells were then placed in 5 ml of medium
stimulated for 30, 90, or 180 min. All plates (except the 100%)
were then washed in PBS, stripped (50 mM glutathione, 0.3 mM
NaCl, 75 mM NaOH, 1% FBS) at 4 °C for 30 min (to remove
remaining cell surface-biotinylated receptors), quenched (PBS
containing 1 mM iodoacetamide, 0.1% BSA), and then lysed in
immunoprecipitation buffer (containing 0.1% Triton X-100,
150 mM NaCl, 25 mM KCl, 10 mM Tris-HCl (pH 7.4), and pro-
tease inhibitors (Roche Applied Science)). Lysates were immu-
noprecipitated (anti-FLAG M2) overnight and incubated for
2 h with recombinant protein G-Sepharose (Life Technologies)
and deglycosylated. Samples were resolved by SDS-PAGE and
visualized with streptavidin overlay (VECTASTAIN ABC
immunoperoxidase reagent, Vector Laboratories).
Apoptosis Assay—HEK293 cells stably expressingN-terminal
FLAG-tagged FPR2/ALX or N333-stop were grown to 50%
confluency in 6-well plates and either untreated or treated with
W peptide for 5 h. Etoposide was used as a positive control.
Cells were lifted in 0.5 ml of PBS/EDTA pelleted at 1000 rpm
and resuspended in binding buffer containing annexin V and
propidium iodide according to the manufacturer’s protocol.
Cells were analyzed on a FACSCalibur with 10,000 events being
analyzed in all cases.
Phospho-ERK and Phospho-JNK Signaling—HEK293 cells
stably expressing N-terminal FLAG-tagged FPR2/ALX or
N333-stop were grown to confluency in 6-well plates and
serum-starved for 4 h prior to experimentation. For time course
experiments, cells were untreated or stimulated with 500 nMW
peptide for 5, 10, or 30 min. For resensitization experiments,
cells were i) untreated, ii) stimulated for 5min with the agonist,
iii) incubated for 30 min agonist and then re-challenged with
vehicle or compound for 5 min, or iv) treated for 30 min with
agonist, washed in PBS, and returned to the incubator for 90
min to allow receptor prior to 5 min of challenge with either
vehicle or drug. In all cases, samples were lysed in 150 l of hot
4 SDS sample buffer containing DTT, separated using SDS-
PAGE electrophoresis, and transferred to nitrocellulose. Blots
were then assessed for phospho-ERK 1/2 or phospho-JNK and
then stripped (stripping buffer, Pierce) and reprobed for total
ERK1/2 or JNK (Cell Signaling). Signal was detected using a
Fusion SL image capture system (PEQLAB).
Statistics—Data were analyzed using one-way ANOVA fol-
lowed by Bonferroni’s t tests between corresponding time
points using GraphPad Prism 6.0 software.
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RESULTS
Mutation of Serine and Threonine Clusters within the C-tail
of FPR2/ALX Results in Altered Arrestin Recruitment and Sub-
cellular Receptor Localization following Endocytosis—Efficient
receptor phosphorylation by GPCR-regulated kinases and
arrestin recruitment have long been implicated as essential in
the regulation of GPCR signaling, avoiding prolonged down-
stream activation (22). Subsequent internalization into endo-
somes and recycling to the plasma membrane serve as a means
for receptor recovery, allowing further receptor activation and
functional resensitization (4). We investigated the role of the
C-tail in receptor endocytosis and recycling of the FPR2/ALX
in response to W peptide (23), utilizing previous mutagenesis
studies as a starting point. Specifically, we made use of the Ser/
Thr clusters identified for human FPR2/ALX (18) and created
three distinct mutants A (Ser-316, Thr-319, and Ser-320), B
(Ser-326, Ser-329, and Thr-332), and AB (Ser-316, Thr-319,
Ser-320, Ser-326, Ser-329, and Thr-332), where serines and
threonines were mutated to alanines (Fig. 1A, indicated in red).
Typically, phosphorylation leads to arrestin recruitment fol-
lowed by receptor endocytosis (22). To test whether these
mutations influenced endocytosis and arrestin recruitment,
HEK293 cells were transfectedwithWTFPR2/ALX,A,B, or
AB, co-expressed with either EGFP -arrestin 1 (-Arr1) or
EGFP-arrestin 2 (-Arr2), and incubatedwith anti-FLAGM1
antibody to specifically label mature receptors on the plasma
membrane (indicated in red) (19). In agreement with previous
studies (11, 12), FPR2/ALX underwent rapid endocytosis
recruiting both -Arr1 and -Arr2 within 5 min of W peptide
agonist addition (optimal concentration of 500 nM) (Figs. 1B
FIGURE 1. Mutation of serines and threonines in the C-tail of FPR2 changes -Arr1 binding patterns. A, illustration of constructed phosphorylation
mutants,A,B, andAB,where red aminoacidsweremutated to alanines.B–E, HEK293 cells expressingN-terminally FLAG-tagged receptor constructs (FPR2,
A,B, orAB) and EGFP-tagged-Arr1. Cells were fedwith anti-FLAGM1 antibody to label receptor and treated as indicated (500 nMWpeptide), then fixed,
permeabilized, and incubated with secondary antibody prior to confocal microscopy. Representative images are shown with scale bars equal to 20 m, and
dotted linesmark the cell boundary.
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and 2A,middle panels), as indicated by a translocation from the
plasmamembrane to a punctate intracellular appearance. After
30 min, FPR2/ALX located in multiple enlarged endosomal
structures dispersed throughout the cytoplasm and remained
co-localized with both -Arr1 and -Arr2 (Figs. 1B and 2A,
lower panels, indicated in yellow). On further investigation, the
enlarged receptor/arrestin-containing structures we observed
(Figs. 1B and 2A, lower panels) were Rab5-positive (Fig. 2F,
yellow staining, see arrows), indicative of trafficking from the
plasma membrane into the early sorting endosomes (24). In
contrast, another rhodopsin-like GPCR, the -opioid receptor
(DOR), showed robust recruitment of only -Arr2 to the
plasma membrane within 5 min of agonist exposure (10 M
DADLE), formed typically smaller puncta, and did not remain
co-localized after 30 min as evident by the more diffuse cyto-
plasmic appearance (Fig. 3, A and B).
The recruitment pattern observed for FPR2/ALXwas typical
to that reported for the angiotensin (AT1R) and the vasopressin
FIGURE 2.Mutation of serines and threonines in the C-tail of FPR2 changes -Arr2 binding patterns. A–D, HEK293 cells expressing N-terminally FLAG-
tagged receptor constructs (FPR2, A, B or AB) and EGFP-tagged -Arr2. Cells were fed with anti-FLAG M1 antibody to label receptor and treated as
indicated (500 nMWpeptide) and then fixed, permeabilized, and incubated with secondary antibody and visualized using confocal microscopy. E, quantifica-
tionof-Arr2 associationwith receptor constructs at 30minofWpeptide treatment expressed as Pearson’s correlation coefficient. Data are represented as the
mean co-localization of at least 30 cells performed on three separate occasions and analyzed using one-way ANOVA with Bonferroni’s t test where ****, p
0.001 when compared with WT FPR2. Error bars indicate mean S.D. F, cells co-expressing WT N-terminally FLAG-tagged FPR2 and EGFP Rab5 were fed with
M1 antibody as in A and incubated for 20min withW peptide. Representative images are shownwith scale bars equal to 20m. Cell boundary is marked by a
dotted line.
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(V2R) receptors. Indeed, previous research has subdivided the
rhodopsin-likeGPCRs into twogroups, the first exhibitinghigher
affinity for -Arr2 and rapid dissociation of the receptor-arrestin
complex (i.e. DOR), with the second showing equal affinities for
-Arr1 and -Arr2 with prolonged, endosomal co-localization
with arrestins following endocytosis (25). These data demonstrate
that FPR2/ALX belongs to this second category.
Comparable with WT FPR2/ALX, mutant A underwent
endocytosis and arrestin recruitment within 5 min, displaying
similar enlarged endosomal structures after 30 min and co-lo-
calizationwith either-Arr1 or-Arr2with equal affinity (Figs.
1C and 2B, arrows). However, mutant B (Figs. 1D and 2C) or
the combined mutant AB (Figs. 1E and 2D) changed the
appearance of both receptor and arrestin. Furthermore, there
was significantly less-Arr2 co-localization after 30min of ago-
nist treatment withmutantB andAB, whereas forA, levels
remained comparable with the FPR2/ALX control (Fig. 2E).
Although these mutated FPR2/ALX forms underwent efficient
endocytosis, they displayed a more clustered appearance typi-
cal of a perinuclear endocytic recycling compartment when
expressing -Arr2 (Fig. 2, C and D, arrows) (26). Furthermore,
following translocation to the plasma membrane, both GFP
-Arr1 and -Arr2 appear to remain at this location after 30
min with far less observed localized with receptors in these
perinuclear compartments; this arrestin pattern is more typical
of that observed with DOR (Fig. 3B) than withWT FPR2/ALX.
Further investigation revealed that following 30 min of agonist
treatment, the B mutant was found to traffic to a compart-
ment that showed distinctive co-localization with the Rab11
recycling endosomemarker (Fig. 4, arrows). Although both the
wild-type FPR2/ALX and the A mutant show some co-local-
ization with Rab11, this was much less pronounced than that
seen for the B (Fig. 4, yellow staining). Altogether, these data
suggest that the Ser/Thr cluster in region B (Fig. 1A) is critical
for continued arrestin interactions at the endosome, andmuta-
tion of these residues results in an altered post-endocytic loca-
tion for the receptor targeting it to a Rab11-positive compart-
ment before recycling back to the plasma membrane occurs.
Truncation of the C-tail of FPR2/ALX but Not the FPR1 Pre-
vents Receptor Recycling—Arrestin has been implicated in the
recycling of the homologous FPR1 (9) and other distinctGPCRs
(27). Next, we used a flow protocol (20, 21) to determine
FIGURE 3. DOR recruits -Arr2. A and B, HEK293 cells were transfected with
N-terminally FLAG-tagged DOR and either EGFP -Arr1 (A) or EGFP -Arr2 (B)
and fedwithM1antibody (1:1000) to labelmature cell surface receptors. Cells
were untreated or stimulated with DADLE (10 M) for 5 or 30 min, fixed, per-
meabilized, and incubatedwith secondary antibody (anti-mouse IgG2bAlexa
Fluor 594, 1:1000) and visualized by confocal microscopy. Representative
images are shown with scale bars equal to 20 m. DELTA, -opioid receptor.
FIGURE 4.Mutation of theB residues confers retention in the Rab11 com-
partment.Cells expressingWTN-terminally FLAG-tagged FPR2,A, orBwere
co-expressedwith EGFP Rab11 and fedwithM1 antibody as in Figs. 1 and 2 and
incubated for 30min withW peptide. Cells were then fixed, permeabilized, and
incubatedwithsecondaryantibody(anti-mouse IgG2bAlexaFluor594,1:1000)
and visualized using confocal microscopy. Representative images are shown
with scale bars equal to 20m (green arrow indicates the Rab11 recycling com-
partment, andwhite arrows show co-localization).
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whether the altered arrestin binding downstream of the FPR2/
ALX phosphorylation mutants had any influence on receptor
recycling following endocytosis and agonist removal. Mature
cell surface receptors on the plasmamembrane were incubated
withM1-conjugated Alexa Fluor 647 and either left untreated
or stimulated with W peptide (500 nM; 30 min); a subsequent
wash with PBS/EDTA removed any remaining surface staining
to specifically label the endocytic pool (indicated by an increase
in fluorescence when compared with the untreated strip con-
trol). Cells were then incubated for 15–90 min in the presence
of PBS/EDTA to quantify receptor recycling; a loss of fluores-
cence indicates recycling andhence exposure to the PBS/EDTA
strip at the cell surface.
In agreement with a previous study (11), FPR2/ALX rapidly
recycled back to the surface within 15 min with complete recy-
cling at 60min after wash, as shown by no significant difference
from untreated samples (Fig. 5A). Interestingly, although both
A and B mutants elicited internalization comparable with
the WT, AB exhibited a reduced fluorescence after 30 min,
indicative of reduced internalization (despite expressing to
comparable surface levels when compared with WT FPR2/
ALX; Figs. 1E and 2D). This reduced internalization may
explain the lack of Ca2 desensitization previously observed by
Rabiet et al. (18) in their investigation using similar phosphor-
ylation-deficient mutations; furthermore, these data may sug-
gest the requirement of other phosphorylation sites/regions
within the receptor to mediate endocytosis.
Despite the observed differences in internalization, all
mutant FPR2/ALX receptors were able to recycle the endocy-
tosed pool as efficiently as the WT form, with complete recy-
cling evident at 60 min after agonist removal. Indeed, the A
mutant appeared to recycle more efficiently than WT FPR2/
ALX (Fig. 5B). Taken together with the data in Figs. 1 and 2, it
appears that the Ser/Thr clusters do not determine the post-
endocytic fate of the FPR2/ALX because efficient recycling is
possible even in the absence of these residues. However, it is
clear that the Ser/Thr clusters do play functional roles in endo-
cytic trafficking, with phosphorylation potentially determining
which compartment the receptor enters and how efficiently it
recycles, rather than the absolute receptor fate per se.
GPCR recycling can be regulated by sequences present in the
distal C terminus, withmotifs identified for the-opioid recep-
tor (28), 2-adrenergic receptor (2AR) (29), and dopamine D1
receptor (D1R) (30) among others (4) where either the trunca-
tion of or the addition of epitope tags or amino acids to the C
terminus resulted in attenuated receptor recycling. In an
attempt to identify potential recycling motifs within the C-ter-
minal region of FPR2/ALX, we made several constructs con-
taining stop codons designed to prematurely truncate theC-tail
at different residues (Fig. 6A) and used the modified method of
flow cytometry (described for Fig. 5) to investigate their post-
endocytic properties. It was observed that truncation at Leu-
325 resulted in reduced receptor expression at the plasma
membrane presumably due to structural changes in stability
FIGURE 5.Mutation of the serines and threonines in the C-tail of FPR2 has no effect on receptor recycling. A–D, flow cytometry was used to analyze the
endocytosis and recycling properties of FPR2,A,B, andAB (see “Experimental Procedures”). HEK293 cells expressing either WT or mutant receptors were
labeled with M1-conjugated Alexa Fluor 647, stimulated with W peptide (500 nM) for 30 min, and either washed in PBS or returned to the incubator in the
presence of PBS/EDTA for 15, 30, 60, or 90min tomonitor the degree of recycling. Data are represented as themean of at least four independent experiments
performed in duplicate analyzed using one-way ANOVAwith Bonferroni’s t test where ****, p 0.0001, ***, p 0.001, **, p 0.01, *, p 0.05when compared
with untreated controls or ####, p 0.0001, ###, p 0.001, #, p 0.05 when compared with W peptide-treated samples. Error bars indicate mean S.D.
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(Fig. 6B). Importantly, truncation of FPR2/ALX at N333-stop,
P342-stop, or T346-stop showed no differences in receptor
endocytosis, but receptor recycling was inhibited in all clones,
as indicated by the maintenance of fluorescence (Fig. 6, C–E),
rather than the decrease observed for the WT receptor (Fig.
5A). Also, the addition of an alanine to the end of the C termi-
nus did not prevent recycling, distinguishing this new sequence
from that seen in the 2AR (Fig. 6F).
Next, we investigated whether a similar sequence exists
within the FPR1 distal C terminus that differs from the
FPR2/ALX by a single lysine (rather than a methionine, Fig.
7A). Consistent with previously published data (9), we found
that FPR1 underwent extensive recycling following agonist
washout (Fig. 7B) in a similar fashion to FPR2/ALX (Fig. 5A).
Interestingly, in contrast to the FPR2/ALX, truncation of the
C-tail in the FPR1 homologue did not attenuate receptor
FIGURE6.Truncationof theFPR2C-tail prevents receptor recycling.A, illustrationof truncationmutantswhere stopcodonswere introducedat aminoacids
Leu-325, Asn-333, Pro-342, or Thr-346 or the addition of a single alanine to the end of the C-tail (ALA). B, WT FPR2 or the truncationmutants were assessed for
cell surface expression by flow cytometry. C–F, the endocytosis and recycling properties of N333-stop (N333), P342-stop (P342), T346-stop (T346), and ALAwas
analyzed by flow cytometry as in Fig. 5. Data are represented as the mean of at least four independent experiments performed in duplicate analyzed using
one-way ANOVAwith Bonferroni’s t test where ****, p 0.0001, ***, p 0.001, **, p 0.01, *, p 0.05when comparedwith untreated controls or ##, p 0.01,
####, p 0.0001 when compared withW peptide-treated samples. There were no significant differences in samples when compared withW peptide-treated
samples. Error bars indicate mean S.D.
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recycling (Fig. 7C) and instead exhibited a time-dependent
decrease in fluorescence comparable with the WT FPR1
(Fig. 7B).
Recycling-deficient FPR2/ALX Results in Cellular Apoptosis
through a Phospho-JNK-mediated Pathway—Given the changes in
arrestin recruitment following mutation of phosphorylation
FIGURE 7. Truncation of the FPR1 C-tail does not prevent receptor recycling. A, alignment of FPR1 and FPR2 C-tail sequences and illustration of truncation
mutant where a stop codon was introduced at amino acid Leu-340 in the FPR1 backbone. L340, L340-stop. B and C, the endocytosis and recycling properties
of WT FPR1 and Leu-340 were analyzed by flow cytometry as in Fig. 5. Data are represented as the mean of at least four independent experiments performed
induplicate analyzedusingone-wayANOVAwithBonferroni’s t testwhere ****,p0.0001, ***,p0.001whencomparedwithuntreated controls or ####,p
0.0001 when compared with W peptide-treated samples. Error bars indicate mean S.D.
FIGURE 8. Attenuated recycling leads to lysosomal targeting and receptor down-regulation. A, HEK293 cells expressing N-terminally FLAG-tagged
N333-stop and EGFP-tagged -Arr2 were fed with anti-FLAG M1 antibody as in Fig. 2, treated with W peptide, and then fixed, permeabilized, and incubated
with secondary antibody and visualized using confocal microscopy. Representative images are shown with scale bars equal to 20 m, and arrows indicate
examples of co-localization. B, quantification of -Arr2 association with FPR2 and N333-stop (N333) at 30-min W peptide treatment expressed as Pearson’s
correlation. Data are represented as the mean co-localization of at least 30 cells performed on three separate occasions and analyzed using one-way ANOVA
with Bonferroni’s t test where ****, p  0.001 when compared with WT FPR2. Error bars indicate mean  S.D. C, HEK293 cells stably expressing FPR2 or
N333-stop were labeled with anti-FLAG M1 antibody and LysoTracker and incubated for 90 min with 500 nM W peptide. Representative confocal images are
shown with scale bars equal to 20 m, and arrows indicate the lysosomal compartment. D, HEK293 cells stably expressing FPR2, N333-stop (N333), P342-stop
(P343), or T346-stop (T346) were surface-biotinylated and either untreated or stimulated with 500 nM W peptide for 30, 90, or 180 min. Receptor fate was
assessed after immunoprecipitation with anti-FLAG M2 antibody, subsequent separation by SDS-PAGE electrophoresis, and streptavidin overlay. The 100%
lane shows total surface receptor labeling, and the STRIP lane indicates the efficiency of the biotin cleavage. NT, non-treatment. Representative immunoblots
are shown.
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sites in theC-tail of FPR2/ALX (Fig. 2), we assessed the ability of
mutant N333-stop to recruit -Arr2. Although showing some
endosomal co-localization with -Arr2 (Fig. 8A, arrows), these
endosomeswere smaller in size than that typically seenwith the
WT FPR2/ALX, and N333-stop exhibited significantly less
-Arr2 co-localization following 30 min of agonist treatment
(Fig. 8, A and B), similar to that observed for the B and AB
mutants (Fig. 2), perhaps indicating transition through the
endosomal compartment.
Lack of receptor recycling following endocytosis could man-
ifest as either an accumulation of receptor in endosomal com-
partments, such as in the truncated D1R (19, 30), or a change of
fate whereby the receptor is transported for lysosomal degrada-
tion, as in the case of the truncated -opioid receptor (19, 28).
HEK293 cells stably expressing either WT FPR2/ALX or
mutant N333-stop were incubated with 500 nMW peptide and
visualized for their co-localization with lysosomes (via Lyso-
Tracker red staining, Fig. 8C, arrows). After 90 min, N333-stop
could be found co-localizedwith lysosomal compartments (Fig.
8C, yellow staining), unlike WT FPR2/ALX, which existed in
distinct structures, and could also be observed having returned
to the plasma membrane. Hence, N333-stop was trafficked
away from the recycling compartments and targeted to the
acidic lysosomes.
To investigate post-endocytic receptor stability following
prolonged agonist treatment, we used HEK293 cells stably
expressing FPR2/ALX or its corresponding mutants and made
use of the biotin protection assay (see “Experimental Proce-
dures”). By using this method, we could follow the fate of only
the mature receptors on the plasma membrane, whereas endo-
cytosed receptors are protected from the strip wash.WTFPR2/
ALX remained stable after 180-min exposure toWpeptide (500
nM), whereas all three mutant (N333-stop, P342-stop, and
T346-stop) receptors showed reduced expression levels at the
same time point, indicative of receptor degradation (Fig. 8D).
Hence, truncation of FPR2/ALX not only prevented recycling
following endocytosis in response to W peptide but also
resulted in a change of fate whereby FPR2/ALX mutants were
targeted to acidic lysosomal compartments and down-regu-
lated following sustained ligand treatment.
Previous studies involving FPR1, using mouse embryonic
fibroblast cells devoid of both-Arr1 and-Arr2, reported fail-
ure of this receptor to recycle with consequent cellular accu-
mulation and apoptosis (10). We hypothesized that failure of
FPR2/ALX to efficiently recycle in response to W peptide
would also impact on cellular apoptosis. We used the classical
annexin A5:propidium iodide flow cytometry protocols to
measure the degree of apoptosis in FPR2/ALXWT and N333-
stop mutant cells. Treatment of native FPR2/ALX for 5 h with
W peptide resulted in minimal cellular apoptosis (Fig. 9, A and
C), whereas apoptosis was markedly increased in cells overex-
pressing N333-stop, the recycling-deficient mutant (Fig. 9, B
and D). Furthermore, N333-stop exhibited a higher basal
apoptosis in untreated samples presumably due to accumula-
tion following constitutive internalization and defective recy-
cling. Hence, these data indicate that efficient internalization
and recycling of FPR2/ALX is both required and necessary for
protection against programmed cell death.
FIGURE 9.Attenuated recycling leads to cellular apoptosis.A and B, cells expressing either FPR2 (A) or N333-stop (N333) (B) were untreated or treated for 5 h
with either etoposide or W peptide, stained with propidium iodide and annexin V, and analyzed using flow cytometry. A representative trace is shown. C and
D, quantification of three experiments performed in duplicate and analyzed using one-way ANOVA with Bonferroni’s t-tests. **, p 0.01, *, p 0.05 when
compared with untreated controls. ##, p 0.01 or #, p 0.05 when compared with W peptide-treated samples. Error bars indicate mean S.D.
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To elucidate the pathways responsible for increased apopto-
sis in N333-stop-expressing cells, phospho-ERK1/2 and phos-
pho-JNK were investigated as possible signaling candidates
(31). Indeed, previous work from this laboratory identified JNK
phosphorylation to precede apoptosis in neutrophils through
activation of an FPR1/FPR2/ALX heterodimer (31). Firstly,
FPR2/ALX- or N333-stop-expressing cells were untreated or
stimulated with W peptide for 5, 10, or 30 min. Both WT and
mutant-expressing cells phosphorylated ERK 1/2 in a similar
fashion, peaking at 5 min and undetectable by 30 min, indica-
tive of receptor desensitization (Fig. 10A). In contrast to
ERK 1/2 signaling, both FPR2/ALX and N333-stop showed
increased and sustained activation of phospho-JNK up to 30
min (Fig. 10B).
Several studies have reported receptor recycling to the
plasma membrane to be important in the recovery of the cellu-
lar response (32–35). To assess whether receptor recycling
resulted in renewed signaling, phospho-ERK 1/2 was investi-
gated in FPR2/ALX- and N333-stop-expressing cell lines. As
observed previously, both receptors evoked robust phospho-
ERK1/2 signaling after 5-min stimulation with W peptide (Fig.
10C). However, no signal could be detected after pretreatment
for 30minwith agonist followed by a 5-min re-challenge, which
is consistent with desensitization of the receptor followed by
endocytosis and removal from the plasmamembrane. Further-
more, following agonist washout and a 90-min recovery period,
re-challenge of FPR2/ALX with agonist exhibited recovery of
the phospho-ERK1/2 response, which was absent from N333-
stop-expressing cells. These data are consistent with FPR2/
ALX internalizing and recycling following agonist washout
(Fig. 5A), allowing receptor resensitization and the ability to
once again respond to ligand at the cell surface. In contrast, the
lack of signal recovery observed in the N333-stop-expressing
cell lines is consistent with the lack of recycling reported in
Fig. 6C.
The FPR2/ALX C-tail Contains a Transplantable Recycling
Motif—Previous publications have reported that DOR under-
goes down-regulation following chronic agonist exposure, with
little evidence for recycling following agonist removal. Trans-
plantation of a recycling motif from either the 2AR or the
-opioid receptorwas enough to reroute the endocytic traffick-
ing of DOR and facilitate recycling of this receptor (28, 36). We
sought to identify whether residues in the C terminus of the
FPR2/ALX could also be transplanted onto DOR to evoke effi-
cient recycling. Three constructs were made introducing sev-
eral amino acids using PCR. These were the addition of the
human influenza HA tag (YPYDVPDYA, DOR-HA) or the last
five (ELQAM, DOR5) or nine (PAETELQAM, DOR9)
amino acids from the distal portion of the FPR2/ALX C-tail
(Fig. 11A). The addition of theHA tag to the C-tail of DOR (37),
although eliciting a slight reduction in endocytosis, did not alter
the recycling properties with the receptor failing to return to
the plasma membrane, indicating that purely adding any tag to
DOR was insufficient to elicit recycling (Fig. 11, B and C). In
comparison, transplantation of either five or nine amino acids
from the most distal portion of the C terminus of FPR2/ALX
afforded receptor recycling following endocytosis (Fig. 11, D
and E).
To further investigate this recycling motif, four further
mutations weremadewithin theDOR5 backbone. Firstly, the
methionine was mutated to a lysine to resemble the most distal
portion of the FPR1C-tail (i.e. ELQAK). Secondly, three further
point mutations were made to the most conserved residues
across the many FPR2 sequences in GenBankTM (ALQAM,
EKQAK, EAQAM). All mutations subsequently attenuated
DOR recycling when compared with DOR5 (Fig. 11F), indi-
cating that these conserved amino acids are all required for
maintaining a functional recycling sequence. There results
demonstrate that the sequence identified in FPR2/ALX is a
bona fide recycling sequence, being both necessary and suffi-
cient for recycling, and is distinct from that of FPR1.
DISCUSSION
FPR2/ALX has long been identified as an important media-
tor of the inflammatory response responding to activation by
FIGURE 10.MAPK signaling of FPR2 and N333-stop. A and B, HEK293 cells
stably expressing either N-terminally FLAG-tagged WT FPR2 or N333-stop
(N333)were serum-starved4hprior to experimentation. Cellswereuntreated
or stimulatedwith 500nMWpeptide for 5, 10, and 30min, lysed, separatedby
SDS-PAGE, and probed for phospho-ERK 1/2 (A) or JNK (B), and then stripped
and reprobed for total ERK 1/2 and JNK. C, for resensitization, phospho-ERK
1/2 was investigated where cells were either untreated, stimulated for 5min,
pretreated with agonist for 30 min, and then re-challenged with vehicle or
drug (desensitized) or pretreated for 30min, washed, and allowed to recover
for 90min at 37 °C before a final re-challenge for 5minwith agonist or vehicle
(resensitization and recycling). Representative blots are shown of at least
three independent experiments.
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both pro-inflammatory and anti-inflammatory ligands. In par-
ticular, activation of this receptor is pivotal in the initiation of
the anti-inflammatory, pro-resolution portion of this cascade.
Failure of resolution prevents the return to cellular homeosta-
sis, resulting in persistent inflammatory conditions. Therefore,
understanding themolecularmachinery of FPR2/ALX function
is critical to understanding physiological and pathophysiologi-
cal inflammatory processes.
We report new evidence that specific Ser/Thr clusters in the
C-tail of FPR2/ALX are responsible for arrestin binding and
targeting to specific subcellular cytoplasmic compartments.
The data presented herein indicate that efficient interaction
FIGURE 11.FPR2 contains a specificmotif that is able to facilitate recyclingof thedegrading-opioid receptor.A, chimeras ofDORas introducedby PCR:
DOR-HA (YPYDVPDYA), DOR5 (ELQAM), andDOR9 (PAETELQAM). B–E, cells transiently expressingWTor chimeric constructswere assessed for endocytosis
and recycling by flow cytometry (see “Experimental Procedures”). Cells were labeled as in Fig. 5 and either untreated or stimulated for 30min with DADLE (10
M) and thenwashedwith PBS/EDTA to assess acute endocytosis, or stimulated and returned to the incubator for 60min in thepresence of PBS/EDTA to assess
receptor recycling.F, pointmutationswere introduced to theDOR5backbone toelucidate specific aminoacidswithin thismotif critical for receptor recycling.
Data are represented as themean of at three independent experiments performed in duplicate analyzed using one-way ANOVAwith Bonferroni’s t test where
****, p 0.0001, ***, **, p 0.01, *, p 0.05 when compared with untreated controls or ####, p 0.0001 or #, p 0.05 when compared with DADLE-treated
samples. Error bars indicate mean S.D.
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with arrestins ensures residence within the early, Rab5-positive
endosome, as well as subsequent rapid recycling (mutant A),
whereas the absence of arrestin interaction (mutant B) pro-
motes transit through to a different, slower recycling compart-
ment likely regulated by Rab11. It will be important in future
studies to determine whether and how these recycling routes
differ and what role the two routes play in the trafficking of the
WT FPR2/ALX. Importantly, FPR2/ALX is able to efficiently
recycle from both compartments, suggesting that the stable
arrestin interaction observed does not determine the endocytic
fate of the receptor. This is in stark contrast to that observed for
FPR1 where mouse embryonic fibroblast cells devoid of both
-Arr1 and -Arr2, although showing no inhibition of endocy-
tosis, were unable to efficiently recycle to the plasmamembrane
(10) and instead remained within the Rab11 compartment. Of
note, the FPR2/ALX B mutant appears to be localized to a
similar, Rab11, compartment following endocytosis but, unlike
FPR1, is still able to recycle. Whether arrestin plays any subtle
role at this stage remains to be determined.
We have identified for the first time a specific recyclingmotif
at the distal portion of the C-terminal tail that, if removed, fails
to influence endocytosis but instead attenuates the ability of
this receptor to recycle, targeting it for degradation. Analysis of
the sequences of several FPR2/ALXwithinGenBank indicates a
consensus sequence of (D/E)XX (where  is any hydropho-
bic residue), although this needs to be validated for other recep-
tors. Alignment of FPR1 revealed that this receptor is missing
themethionine at itsmost distal residue and instead possesses a
lysine at this position. However, this lysine is neither necessary
nor sufficient for recycling because truncation failed to attenu-
ate return of the FPR1 to the plasmamembrane. Indeed, muta-
tion of any of these conserved residues within the distal C ter-
minus of FPR2/ALX removes the ability of this sequence to
transfer recycling onto the DOR. Interestingly, this sequence
does not appear to be conserved among any other GPCRs, and
thus identification of the recycling protein is an interesting area
of study as it may represent a new target for therapeutic
intervention.
Themost widely understoodGPCR recycling sequence is the
type I PDZ ligand foundon2AR,which allows interactionwith
sorting nexin 27 and recycling mediated via the retromer (38,
39). The ELQAM sequence present on the FPR2/ALX, how-
ever, is not a canonical type I PDZ ligand, and the addition of an
alanine residue did not inhibit recycling (in contrast to the
2AR (29)) altogether, suggesting the involvement of a different
recycling pathway. It therefore remains to be seen whether any
of the processes described for other receptors (e.g.SNX27, ret-
romer, etc.) are involved in mediating FPR2/ALX recycling,
although the fact that the conserved sequence cannot be iden-
tified in any other GPCRs might suggest the existence of novel
interacting partner(s) that regulate the recycling of the FPR2/
ALX localization.
It has long been established thatGPCR endocytosis and recy-
cling serve to modulate receptor signaling, thereby preventing
overstimulation.More recent research has revealed that signal-
ing via GPCRsmay also be controlled via biased agonism of the
receptor. Indeed, transient ERK 1/2 phosphorylation has been
found to be G-protein-dependent, whereas more sustained sig-
naling occurs via a -Arr2-mediated pathway (40). In this
study, we provide evidence for both ERK 1/2 and JNK activa-
tion, which have been previously reported to be Gi-dependent,
rather than an arrestin-mediated response (41). Additionally,
Wagener et al. (10) report that arrestin-mediated recycling of
FPR1 is paramount in the suppression of the apoptotic signal.
Therefore, it seems that the important anti-apoptotic effect
relies on the ability of the receptor to recycle and resensitize the
receptor rather than ligand bias per se.
The cytoplasmic mechanism regulating recycling of FPR2/
ALX therefore remains an important avenue for further study
to fully define the complex biology of this receptor. Of impor-
tance, modification of the fate of FPR2/ALX had significant
effects on cell viability following agonist treatment. However,
no obvious differences in JNK signaling were observed between
FPR2/ALX and the N333-stop recycling-deficient mutant, nor
in ERK 1/2 responses. This was a somewhat surprising result
because one would predict a more robust JNK signal in cells
exhibiting increased apoptosis. This suggests that other pro-
apoptotic pathwaysmay be involved. However, the observation
of a rise in apoptotic cells when expressing the recycling-defec-
tive FPR2/ALX suggests that continued recycling is important
for the homeostatic maintenance of anti-apoptotic signaling as
seen by a recovery of ERK 1/2 phosphorylation inWT cells. It is
noteworthy that arrestin reportedly plays a role in suppressing
apoptotic signaling by a number of GPCRs including the FPR1
(42). Our data are consistent with this observation and suggest
that the multiple rounds of endocytosis and recycling of the
WT FPR2/ALXmaintain arrestin signaling, whereas the N333-
stop does not. This suggests an arrestin-mediated anti-apoptotic
signal that needs further investigation, as will confirmation of the
importanceof receptor trafficking inmorephysiologically relevant
preparations such as neutrophils andmacrophages.
Collectively, these data suggest that, in addition to activation
and cellular signaling, the endocytic trafficking of GPCRs plays
an important role in how FPR2/ALX functions in the inflam-
matory response. It is conceivable that the design of specific
“trafficking-biased” ligands that do not drive endocytosis or
recycling may be more apoptotic, and hence more advanta-
geous, in the treatment of chronic inflammation.
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